About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Short-Squeeze Target Anavex Life Sciences Gains Traction

Scientific analysis of Alzheimer

Anavex Life Sciences (NASDAQ: AVXL) is a short-squeeze candidate because its share prices are rising on good news, institutional and analyst support is growing, and the short-sellers are selling into the rally. Short interest topped 23% at the end of November and is unlikely to have fallen much since because they spiked to a one-year high, showing a high conviction—plenty of fuel for a short squeeze. 

However, the rally beginning in late October was sparked by positive results from a 2b/3 study that showed a more than 36% reduction in Alzheimer's progression within the target group. Estimated at over $15 billion in potential sales, it is good news for the pharmaceutical company and investors, and it is compounded by numerous details that suggest a short squeeze is coming. The once-daily treatment makes it easy to use and safer than competitors, not taken orally. It is unlikely to require the same level of monitoring and is an industry-disrupting product. 

The treatment, labeled Anavex 2-73 and named blarcamesine, was even more effective, nearly 50%, within a smaller subgroup. It may also be effective in treating a wide range of CNS disorders. If so, the potential for market value tops the $20 billion mark for annual sales. Sales may begin soon. The company has already filed for marketing approval in the EU. It may receive it as early as H1 2025, setting it to begin generating significant revenue by the end of the year. 

Analysts and Institutions Provide Tailwinds for Anavex Stock Price

Analysts are bullish on the stock but have yet to adjust their revenue and earnings forecasts for EU approval of blarcamesine and its market-disrupting potential. The analysts' coverage is also light, with only four tracked by MarketBeat, which means a strong upgrade cycle is coming, including increasing coverage. As it is, the forecasts are robust, expecting the company to generate upward of $8 billion in annual sales and $40 per share in earnings by 2032. Still, no revenue or earnings are forecasted for 2025, and the $8 billion target is cautious compared to blarcamesine’s potential, so the earnings estimate upgrade cycle could begin in early 2025 and be vigorous.

The analysts' sentiment and stock price targets are bullish and warming. The consensus of four is a Buy with a price target of $43, about 400% above the critical resistance target. The freshest targets align with that outlook, set after the blarcamesine news was released, and are likely to be followed by increasing coverage and price targets in 2025. The critical detail is that the consensus is well above the $10.50 resistance target and will likely be reached quickly if the target is broken. 

Institutional activity provides additional lift to this biopharma market and is likely to continue or strengthen its trend in 2025. The institutions, which own only about 32% of the stock, have bought on balance every quarter in 2024, and total activity ramped up in Q4. Q4 buying activity outpaced selling by nearly 1.5:1, hitting an almost two-year high as institutions like Charles Schwab and Vanguard Group gain exposure to the opportunity. 

Anavex Life Sciences' Strong Technicals Point to Robust Upside

The technical outlook for Anavex stock is robust. The market shows strong, rising support at significant moving averages, echoed by the MACD and stochastic indicators. The takeaway is that upward price pressure is building, and there is still room for the market to run before becoming overbought. A move above the critical resistance point is likely. 

The simple target for bullish traders is a move above the critical $10.50 level equal to the price magnitude of the reversal pattern that came before it, which is $7.15. That puts the market near $17.65, well below the analyst consensus. The bull-case scenario is a move above the critical resistance equal to the percentage gain from the bottom of the head-and-shoulders reversal pattern to the neckline, which is 230%. A move of 230% puts this market at $35, still well below the analysts' consensus but well on the way. 

Anavex AVXL stock chart

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.